Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Oncolytics Biotech Inc. (T:ONC)

Business Focus: Biotechnology & Medical Research (NEC)

INK Edge Outlook

This company is also listed in the United States as ONCY on the NASDAQ. Click here to get the live US quote and see if there are any SEC insider filings..

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for ONC within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Mar 06, 2024 08:00 ET
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - March 6, 2024) - Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on developments for pancreatic cancer treatments, featuring Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology.
Read full article
Mar 05, 2024 08:30 ET
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
FN Media Group News Commentary - Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and other parts of the world is one of the factors driving the need for the drugs used...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.47
--
--
Price to Sales - TTM
--
2.74
3.34
Price to Book - most recent quarter
3.83
2.80
2.09
Price to Cash Flow per share - TTM
--
6.59
9.70
Price to Free Cash Flow per share - TTM
--
26.65
14.99
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Feb 29, 2024303,732-2,330
Feb 15, 2024306,062-40,636
Jan 31, 2024346,698-2,528
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company's primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

See business summary

 

Twitter

Search (past week) for $ONC.CA

  • No tweets found